title: Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation.
authors.forename: P
authors.initials: P
authors.lastname: Vandenberghe
authors.forename: N
authors.initials: N
authors.lastname: Boeckx
authors.forename: E
authors.initials: E
authors.lastname: Ronsyn
authors.forename: R
authors.initials: R
authors.lastname: Decorte
authors.forename: G
authors.initials: G
authors.lastname: Verhoef
authors.forename: A
authors.initials: A
authors.lastname: Hagemeijer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001854:Bone Marrow Cells / Q000473:pathology; D016026:Bone Marrow Transplantation; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy; D007958:Leukocyte Count; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate